Santhera Partners with Biomedica To Distribute AGAMREE® (Vamorolone) For Duchenne Muscular Dystrophy Treatment In Russia

Santhera Pharmaceuticals has entered into an exclusive agreement with Biomedica for the distribution of AGAMREE (vamorolone) in Russia. The therapy is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and older. Under the terms of the agreement, Santhera will receive a percentage of net sales, consistent with the company’s previous distribution arrangements. 

Commercial sales of AGAMREE in Russia are expected to commence in the first quarter of 2026. Through this collaboration, access to AGAMREE will be expanded for patients living with DMD across the country, supported by both regional and national managed access programs. It is estimated that approximately 1,400 individuals in Russia are affected by DMD, highlighting the importance of this agreement in addressing a critical medical need

Dario Eklund, Chief Executive Officer of Santhera, said in a statement, “This agreement will enable more children to access this important DMD treatment, and is the latest in a series of global agreements secured in 2025. We look forward to working closely with Biomedica in the months ahead.” 

Oleg Parosin, Founder and Chief Executive Officer of Biomedica, mentioned, “Our deep expertise in neurology and DMD, particularly with therapies that complement AGAMREE, combined with our track record of successful partnerships with leading EU and US companies, positions us as a strong and trusted partner for Santhera in Russia. We look forward to working together to accelerate access and ensure the availability of AGAMREE from early next year, enabling even more patients to benefit from this essential therapy.”